Many clinical trial results not shared, creating 'blind spot'

Less than 40% of the results of clinical trials conducted at leading academic medical centers were shared within two years of completion, Yale School of Medicine researchers report in a new study published in the current issue of the British Medical Journal.

"Not only was performance poor, but there was significant variation across the academic medical centers we studied," said Dr. Nihar Desai, assistant professor of medicine, section of cardiology at Yale School of Medicine and a researcher at the Yale Center for Outcomes Research and Evaluation.

Desai said randomized clinical trials are the gold standard in terms of testing the efficacy and safety of drugs, devices, and treatment strategies, so disseminating the results is of vital importance.

"Researchers also have an ethical responsibility to the patients enrolled in the study to make the results available," he said. "Providers and patients will never be able to make evidence-based health care decisions if the data is not in the public domain. In addition, future research cannot benefit from what other researchers have already done if results are not reported and/or published in a timely fashion."

Desai and his co-authors previously studied the rates of results reporting and publication of clinical trials sponsored by the National Institutes of Health and by pharmaceutical companies. They decided to extend that prior work by looking at the dissemination of clinical trial results across leading academic institutions. The team reviewed over 4,300 clinical trials and examined how many were published or had results reported on ClinicalTrials.gov within 24 months of the studies' completion.

The team saw a three-fold variation in performance, with some institutions disseminating 16% of their completed clinical research, while others disseminated 55%.

"This is yet another blind spot in the clinical research enterprise, and we hope our findings will serve as a call to action," said Desai. "Academic medical centers are uniquely positioned to lead this effort. They are dedicated to generating knowledge to improve health and health care. We hope our study will lead to a renewed commitment to our professional values and the mission of academic centers to not only conduct rigorous scientific investigation, but to share the results in a timely and transparent fashion."

Other authors on the study included first author Ruijun Chen, Joseph S. Ross, Weiwei Zhang, Katherine H. Chau, Brian Wayda, Karthik Murugiah, Daniel L. Lu, Amit Mittal, and senior author Harlan M. Krumholz.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]